Population Pharmacokinetics of an Angiotensin II Receptor Antagonist, Telmisartan, in Healthy Volunteers and Hypertensive Patients

Wienen, 1993, Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277, Br. J. Pharmacol., 110, 245, 10.1111/j.1476-5381.1993.tb13800.x Wienen, 2000, A review on telmisartan: a novel, long- acting angiotensin Il-receptor antagonist, Cardiovasc Drug Rev., 18, 127, 10.1111/j.1527-3466.2000.tb00039.x Neutel, 1998, Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension, Adv. Ther., 15, 206 Smith, 2000, Dose response and safety of telmisartan in patients with mild to moderate hypertension, J. Clin. Pharmacol., 40, 1380, 10.1177/009127000004001210 Stangier, 2000, Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients, J. Int. Med. Res., 28, 149, 10.1177/147323000002800401 Stangier, 2000, Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers, J. Clin. Pharmacol., 40, 1312, 10.1177/009127000004001202 Stangier, 2000, Pharmacokinetics and safety of intravenous and oral telmisartan 20mg and 120mg in subjects with hepatic impairment compared with healthy volunteers, J. Clin. Pharmacol., 40, 1355, 10.1177/009127000004001207 Williams, 2000, The role of population pharmacokinetics in drug development in light of the Food and Drug Administration’s ‘Guidance for industry: population pharmacokinetics’, Clin. Pharmacokinet., 39, 385, 10.2165/00003088-200039060-00001 FDA, 1999 Ogihara, 2002, Pharmacokinetic evaluation of an angiotensin II AT1 receptor antagonist, BIBR277 (Telmisartan) in hypertensive patients, Jpn. Pharmacol. Ther. (in Japanese), 30, S271 Ogihara, 2002, Pharmacokinetics of BIBR277 (Telmisartan) in hypertensive patients with renal insufficiency, Jpn. Pharmacol. Ther. (in Japanese), 30, S183 Ogihara, 2002, Pharmacokinetics of BIBR277 (Telmisartan) in patients with essential hypertension, Jpn. Pharmacol. Ther. (in Japanese), 30, S235 Irie, 2002, Influence of food on the bioavailability of single oral dose of BIBR277 (Telmisartan), Jpn. Pharmacol. Ther. (in Japanese), 30, S201 Boeckmann, 1998 Ette, 1997, Stability and performance of a population pharmacokinetic model, J. Clin. Pharmacol., 37, 486, 10.1002/j.1552-4604.1997.tb04326.x Israili, 2000, Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension, J. Hum. Hypertens., 14, S73, 10.1038/sj.jhh.1000991 Sharpe, 2001, Telmisartan: a review of its use in hypertension, Drugs, 61, 1501, 10.2165/00003495-200161100-00009 Schmid, 1996, In vivo and in vitro biotransformation of telmisartan, human hepatocyte cultures as an aid in human metabolic studies, Exp. Toxicol. Pathol., 48, 387 Ebner, 1999, In vitro glucuronidation of telmisartan, a novel angiotensin II receptor antagonist, J. Hum. Hypertens., 13, S12 Mackenzie, 2000, Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance, Clin. Chem. Lab. Med., 38, 889, 10.1515/CCLM.2000.129